The research, led by Liang-rui Qin and Can Hu of the State Key Laboratory of Ultrasound in Medicine and Engineering at Chongqing Medical University, together with colleagues including corresponding authors Yong-hong Du and Dai-rong Li, focused on a deceptively straightforward therapeutic idea: deliver oxygen-generating capacity directly into the granuloma microenvironment. Catalase is an enzyme that breaks down hydrogen peroxide into water and molecular oxygen. By injecting catalase locally into tuberculous granulomas at defined stages of infection, the team hoped to relieve the hypoxia, the severe oxygen depletion, that characterizes these lesions and that has long been suspected of undermining both immune function and drug efficacy.

To test the concept, the researchers established a murine subcutaneous tuberculous granuloma model using Bacillus Calmette-Guérin, or BCG, the attenuated mycobacterial strain best known as the tuberculosis vaccine. Mice were divided into treatment groups receiving either catalase, cobalt chloride, a chemical that mimics hypoxia, or a saline control. Crucially, the interventions were timed: one group received treatment at day six after infection, representing an early stage of granuloma formation, while another received it at day twelve, when lesions were more established. The team then assessed outcomes using a battery of techniques including histopathology, immunohistochemistry, immunofluorescence, enzyme-linked immunosorbent assays, and lipidomics, an analytical approach that profiles the full repertoire of lipid species in tissue.

The baseline findings were sobering. As BCG infection progressed, the granulomas became progressively more hypoxic, and this deterioration was accompanied by vascular dysfunction, visible as reduced expression of CD31, a marker of endothelial cells, and alpha-smooth muscle actin, a marker of vascular mural cells. Collagen deposition increased, scarring the lesions and further restricting blood flow. Lipid accumulated within the tissue, and bacterial load, measured as colony-forming units, climbed in parallel. In other words, the granuloma behaves like a self-reinforcing vicious cycle: poor vasculature starves the tissue of oxygen, hypoxia damages vessels further and promotes fibrosis and fat buildup, and the worsening microenvironment favors bacterial persistence.

Against this backdrop, the results of early catalase intervention stood out sharply. When catalase was administered at day six, the treatment downregulated hypoxia inducible factor-1 alpha, the master molecular switch that cells activate under low oxygen, along with vascular endothelial growth factor, a signaling protein that hypoxic tissues produce to stimulate new but often dysfunctional blood vessel growth. With the hypoxic burden lifted, the vascular structure inside the granulomas improved, as did vessel permeability, potentially opening a window for drugs that would otherwise fail to reach the bacteria. Collagen and lipid deposition both declined, indicating that the fibrotic and metabolic deterioration of the lesion had been blunted.

Perhaps the most technically intriguing finding came from the lipidomics analysis. Early catalase treatment did not simply reduce lipid accumulation indiscriminately; it specifically reshaped the lipid profile of the granuloma. The phospholipid species phosphatidylserine 18:0/18:0 was downregulated, while multiple subtypes of phosphatidylinositol and phosphatidylethanolamine were upregulated. This specificity matters because mycobacteria are notorious lipid manipulators: they co-opt host lipid metabolism to build their own protective niches inside macrophages, and aberrant lipid handling within granulomas has been linked to bacterial persistence and lesion necrosis. The finding suggests that oxygen restoration does not merely improve tissue plumbing but actively recalibrates the metabolic landscape on which the bacteria depend.

Timing, however, proved to be everything. When catalase was given at day twelve, well after the granulomas had matured, the therapeutic benefit was markedly limited. The late-stage lesions, already entrenched in hypoxia, fibrosis, and lipid dysregulation, apparently could not be rescued by a single round of oxygen-generating enzyme therapy. Conversely, when the researchers injected cobalt chloride to chemically induce hypoxia, every pathological measure worsened: vascular markers fell further, collagen and lipid deposition increased, and the lesions deteriorated across the board. This reciprocal experiment strengthens the causal argument that hypoxia is not merely correlated with granuloma progression but actively drives it.

The implications for tuberculosis therapy are potentially significant. Current drug regimens for tuberculosis require months of multidrug therapy, and treatment failure is often attributed to poor drug penetration and the metabolically dormant state that bacteria adopt in hypoxic lesions. If restoring oxygenation can normalize granuloma vasculature and reverse the metabolic conditions that shelter persistent bacteria, catalase-based local oxygen therapy could, in principle, serve as an adjunct that makes existing antibiotics work better, rather than a replacement for them. The study’s authors note that their findings suggest a potential application prospect in animal models that more closely recapitulate human tuberculosis, an important caveat, since the subcutaneous BCG model, while tractable and ethically manageable, differs in key respects from pulmonary infection with virulent M. tuberculosis in humans.

Those caveats deserve emphasis. BCG is an attenuated organism, and the granulomas in this model form in the skin rather than the lung, where the architecture of human tuberculous lesions, including caseous necrosis and cavitation, presents additional barriers. The dosing, delivery route, and safety profile of local catalase administration would all need to be established in more faithful models before any translation toward patients could be contemplated. Nonetheless, the study offers a mechanistically grounded proof of concept that the pathological microenvironment of a granuloma is a druggable target in its own right, and that the window for intervening is early, before fibrosis and lipid derangement become irreversible.

What makes the work resonate beyond tuberculosis is its broader message about infectious disease: the battlefield matters as much as the combatants. Rather than attacking the bacteria directly, this approach remodels the tissue ecosystem in which the bacteria survive, targeting hypoxia signaling, vascular integrity, and lipid metabolism simultaneously. As researchers increasingly recognize that chronic infections are sustained by microenvironmental niches, strategies that restore normal tissue physiology, whether through oxygen-generating enzymes, vascular repair, or metabolic modulation, may complement the antibiotic arsenal in ways that new drugs alone cannot. For a disease that still kills well over a million people each year, even a modest improvement in drug penetration and bacterial clearance inside granulomas could translate into shorter cures and fewer treatment failures. The Chongqing team’s catalase experiments are an early step, but they point toward a reframing of tuberculosis therapy: treat the lesion, not just the microbe.

Subject of Research: Catalase-based local oxygen therapy targeting hypoxia and lipid metabolism in tuberculous granulomas

Article Title: Therapeutic effects of early catalase intervention in tuberculous granulomas: targeting hypoxia and lipid dysregulation

Article References: Therapeutic effects of early catalase intervention in tuberculous granulomas: targeting hypoxia and lipid dysregulation. (n.d.). https://doi.org/10.1186/s12879-026-14516-8

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14516-8

Keywords: tuberculosis, granuloma, catalase, hypoxia, HIF-1alpha, oxygen therapy, BCG, lipidomics, vascular dysfunction, fibrosis, mouse model, BMC Infectious Diseases